|
|
|
18.11.25 - 17:33
|
Merck Announces First-Quarter 2026 Dividend (Business Wire)
|
|
|
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the first quarter of 2026. Payment will be made on Jan. 8, 2026, to shareholders of record at the close of business on Dec. 15, 2025.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every d...
|
|
|
18.11.25 - 13:39
|
AKTIONÄR-Top-Tipp Merck & Co: Kurssprung – da geht noch mehr (Der Aktionaer)
|
|
|
Mit einem Kursplus von rund 3,5 Prozent setzt sich die Aktie von Merck & Co in einem schwachen Gesamtmarkt an die Spitze im US-amerikanischen Leitindex Dow Jones. Frische Studiendaten verhelfen dem defensiven Titel zu einem erneuten Kurssprung – und die milliardenschwere Übernahme von Acceleron Pharma zahlt sich weiter aus....
|
|
|
18.11.25 - 11:01
|
Merck & Co Aktie: Mega-Deal mit Cidara entfacht neue Kursfantasie (Aktiencheck)
|
|
|
Charlotte (www.aktiencheck.de) - Merck & Co-Aktienanalyse der Bank of America (BofA):
BofA-Analyst Tim Anderson habe das Kursziel für die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) von 98 auf 105 USD angehoben und das "buy"-Rating bestätigt. Der Deal mit Cidara werde als vernünftig bezeichnet, da das experimentelle Grippemittel des Unternehmens ein neuartiges Asset mit hoher technischer Erfolgschance darstelle und zudem gut zu Mercks Infektionskrankheiten-Portfolio passe, Zudem sei die Merck-Aktie, angesichts des Wachstums, das der US-Pharmakonzern kurz- wie langfristig liefern dürfte, aktuell zu günstig bewertet, heiße es in einer aktuellen Research Note. [mehr]...
|
|
|
|
|
|
|
17.11.25 - 14:03
|
Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors (Business Wire)
|
|
|
Financing accelerates development of clinical-stage assets SLV-154 and SLV‑324, both featuring Solve's CloakLink™ linker technology
Funding round was led by Yosemite, with participation from new investors Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, and all existing investorsSAN DIEGO--(BUSINESS WIRE)--#ADC--Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, today announced it has raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink™ linker platform.
The round was led by Yosemite, with participation from Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., and SymBiosis, and existing investors Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, General Atlantic, and Surveyor Capital (a Citadel company). This lat...
|
|
|
14.11.25 - 18:36
|
Merck to Buy Cidara in $9.2B Deal as Patent Deadline Looms (Bloomberg)
|
|
|
Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its blockbuster cancer drug Keytruda.
Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday's closing price, for a total transaction value of about $9.2 billion, the companies said Friday in a statement. Bloomberg's Madison Muller joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)...
|
|
|
|
|
|
|
14.11.25 - 13:42
|
Merck To Acquire Cidara For $221.50/shr (AFX)
|
|
|
KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) and Cidara Therapeutics, Inc. (CDTX) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per s......
|
|
|
|
|
|
|
14.11.25 - 07:36
|
Paukenschlag: Merck & Co vor dem nächsten Übernahme-Coup? (Der Aktionaer)
|
|
|
Nach der erfolgreichen milliardenschweren Übernahme von Verona Pharma scheint sich der US-amerikanische Pharma-Riese Merck & Co das nächste größere Akquisitionsziel ausgeschaut zu haben. Laut einem Bericht der Financial Times (FT) zufolge hat das Unternehmen ein Auge auf Cidara Therapeutics geworfen....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
